<DOC>
	<DOCNO>NCT00319696</DOCNO>
	<brief_summary>The aim study collect long-term efficacy , tolerability safety data bosentan Systemic Sclerosis ( SSc ) patient suffer ischemic digital ulcer ( DUs ) .</brief_summary>
	<brief_title>Bosentan Digital Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>· Patients SSc accord classification criterion American College Rheumatology SSc patient least one DU baseline qualify CU ( see definition section 3.2.2 ) CU occur &lt; 3 month &gt; 1 week prior randomization The subset patient SSc felt high risk DUs identify screen period eligible enrollment CU develop . Male female patient &gt; /= 18 year age Women childbearing potential must negative pretreatment pregnancy test use reliable method contraception study treatment least 3 month study treatment termination . Women childbearing potential define postmenopausal ( i.e. , amenorrhea least 1 year ) , surgically naturally sterile . Signed informed consent · DUs due condition SSc Severe PAH ( WHO class III IV ) Systolic blood pressure &lt; 85 mmHg . Hemoglobin concentration &lt; 75 % low limit normal range AST and/or ALT value great 3 time upper limit normal Moderate severe hepatic impairment , i.e. , ChildPugh Class B C Severe malabsorption severe organ failure ( e.g. , lung , kidney ) lifethreatening condition Pregnancy breastfeed Previous treatment bosentan Treatment following : glibenclamide ( glyburide ) , fluconazole , cyclosporine A , tacrolimus calcineurin inhibitor 1 week prior randomization Local injection botulinum toxin affect finger 1 month prior randomization Treatment parenteral prostanoids ( prostaglandin E , epoprostenol , treprostinil sodium prostacyclin analog ) 3 month prior randomization Treatment inhale oral prostanoids one month prior randomization Systemic antibiotic treat infection DUs 2 week prior randomization Treatment phosphodiesterase inhibitor sildenafil , except intermittent treatment male erectile dysfunction Body weight &lt; 40 kg Patient condition prevent compliance protocol adhere therapy Patient receive investigational product within 1 month precede screen Known hypersensitivity bosentan excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>systemic sclerosis</keyword>
	<keyword>digital ulcer</keyword>
	<keyword>bosentan</keyword>
	<keyword>open label</keyword>
	<keyword>finger ulcer</keyword>
</DOC>